Applied Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Issuance of options in-lieu of bonus
Amortization of insurance premium
Amortization of operating lease right-of-use assets
Payment of security deposit and leasehold improvements for long-term lease
Change in operating lease liability
Amortization of leasehold improvements
Change in net operating lease liability
Change in fair value of warrant liabilities
Changes in operating assets and liabilities:
Financed insurance premium
Prepaid expenses
Accounts payable
Accrued expenses and other current liabilities
Other liabilities
Net cash used in operating activities

INVESTING ACTIVITIES:
Purchase of available-for-sale securities
Proceeds from sale of available-for-sale securities
Proceeds from maturities of available-for-sale securities
Net cash provided by investing activities
FINANCING ACTIVITIES:
Proceeds from secondary public offering, net of cash issuance costs of $739
Proceeds from June Offering issuance of shares and pre-funded warrants
Payment of offering costs
Private Placement
Shelf Registration Statement
Proceeds from issuance of common stock, pre-funded warrants and reissuance of treasury stock, net of issuance costs
Proceeds from financed insurance premium
Repayments of short-term borrowings
Exercise of stock options for common stock under Equity Incentive Plan
Exercise of Warrants
Net cash provided by financing activities

NET INCREASE IN CASH AND CASH EQUIVALENTS
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Operating lease right-of-use asset obtained in exchange for operating lease liability
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Initial measurement of warrant liability
Operating lease right-of-use asset obtained in exchange for operating lease liabilities
Offering costs in accrued expenses
Shelf Registration Statement
Total offering costs in accrued expenses

Conversion of warrant liabilities to equity for warrant exercises
Unrealized gain (loss) on marketable securities
Reclassification of prefunded warrant liability to equity

Comments